SCAI 2026 Treatment and Management of Complex Peripheral Arterial Disease-Does Drug Choice Matter: Paclitaxel vs. Limus, Dr. Mohan

Does Drug Choice Matter: Paclitaxel vs. Limus, Dr. Mohan

Video Transcription

Video Summary

The speaker compares paclitaxel and sirolimus for peripheral artery disease drug-coated balloons. Paclitaxel has strong existing data and easy vessel delivery, but concerns include embolization, possible mortality signal, and weaker below-the-knee results. Sirolimus may be safer and gentler, but required new delivery technologies like microreservoirs and nano-encapsulation to achieve effective tissue retention. New data show sirolimus can match paclitaxel in primary patency and may offer promising hard outcomes, including noninferiority in some studies. The speaker concludes that more data and continued device development are needed, especially for below-the-knee disease.

Asset Caption

closed captions are computer-generated

Keywords

paclitaxel

sirolimus

peripheral artery disease

drug-coated balloons

below-the-knee disease